Recombinant bacille Calmette–Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis

Journal of Microbiology, Immunology and Infection

Volumn 50, Issue 1, 2017, Pages 90-96

  Chen, Yih Yuan ^a   Lin, Chih Wei ^a   Huang, Wei Feng ^a   Chang, Jia Ru ^a   Su, Ih Jen ^a   Hsu, Chih Hao ^a   Cheng, Han Yin ^a   Hsu, Shu Ching ^a   Dou, Horng Yunn ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Mycobacterium tuberculosis; recombinant bacille Calmette Guerin; vaccine

Indexed keywords

AG85B PROTEIN; BACTERIAL PROTEIN; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 12; RECOMBINANT BCG VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85B, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; CFP-10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BCG VACCINATION; BONE MARROW DERIVED MACROPHAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INNATE IMMUNITY; LUNG; MOUSE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SPLEEN; SPLEEN CELL; TH1 CELL; TH1 TH2 BALANCE; TUBERCULOSIS; ANIMAL; C3H MOUSE; C57BL MOUSE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; MACROPHAGE; MICROBIOLOGY; MONONUCLEAR CELL; MYCOBACTERIUM BOVIS; SECRETION (PROCESS);

ACYLTRANSFERASES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; LUNG; MACROPHAGES; MICE, INBRED C3H; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 84923630435     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.11.019     Document Type: Article

References (31)

1. 1 al-Kassimi, F.A., al-Hajjaj, M.S., al-Orainey, I.O., Bamgboye, E.A., Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?. Am J Respir Crit Care Med 152 (1995), 1575–1578.
2. 2 Colditz, G.A., Brewer, T.F., Berkey, C.S., Wilson, M.E., Burdick, E., Fineberg, H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (1994), 698–702.
3. 3 Brewer, T.F., Colditz, G.A., Relationship between bacille Calmette-Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 20 (1995), 126–135.
4. 4 Chen, Y.Y., Chang, J.R., Huang, W.F., Kuo, S.C., Su, I.J., Sun, J.R., et al. Genetic diversity of the Mycobacterium tuberculosis Beijing family based on SNP and VNTR typing profiles in Asian countries. PLoS One, 7, 2012, e39792.
5. 5 Huang, S.F., Su, W.J., Dou, H.Y., Feng, J.Y., Lee, Y.C., Huang, R.M., et al. Association of Mycobacterium tuberculosis genotypes and clinical and epidemiological features—a multi-center study in Taiwan. Infect Genet Evol 12 (2012), 28–37.
6. 6 Chang, J.R., Chen, Y.Y., Huang, T.S., Huang, W.F., Kuo, S.C., Tseng, F.C., et al. Clonal expansion of both modern and ancient genotypes of Mycobacterium tuberculosis in Southern Taiwan. PLoS One, 7, 2012, e43018.
7. 7 Salerno, E., Yuan, Y., Scaglione, B.J., Marti, G., Jankovic, A., Mazzella, F., et al. The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia. Cytometry B Clin Cytom 78:Suppl. 1 (2010), S98–109.
8. 8 Bifani, P.J., Mathema, B., Kurepina, N.E., Kreiswirth, B.N., Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 10 (2002), 45–52.
9. 9 Mokrousov, I., Ly, H.M., Otten, T., Lan, N.N., Vyshnevskyi, B., Hoffner, S., et al. Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: clues from human phylogeography. Genome Res 15 (2005), 1357–1364.
10. 10 Lin, C.W., Su, I.J., Chang, J.R., Chen, Y.Y., Lu, J.J., Dou, H.Y., Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice. APMIS 120 (2012), 72–82.
11. 11 de Vos, M., Muller, B., Borrell, S., Black, P.A., van Helden, P.D., Warren, R.M., et al. Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57 (2013), 827–832.
12. 12 Campbell, P.J., Morlock, G.P., Sikes, R.D., Dalton, T.L., Metchock, B., Starks, A.M., et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of. Mycobacterium tuberculosis. Antimicrob Agents Chemother 55 (2011), 2032–2041.
13. 13 Pholwat, S., Heysell, S., Stroup, S., Foongladda, S., Houpt, E., Rapid first- and second-line drug susceptibility assay for Mycobacterium tuberculosis isolates by use of quantitative PCR. J Clin Microbiol 49 (2011), 69–75.
14. 14 Plinke, C., Walter, K., Aly, S., Ehlers, S., Niemann, S., Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo. Antimicrob Agents Chemother 55 (2011), 2891–2896.
15. 15 Kao, F.F., Mahmuda, S., Pinto, R., Triccas, J.A., West, N.P., Britton, W.J., The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. PLoS One, 7, 2012, e34991.
16. 16 Wang, X., Barnes, P.F., Huang, F., Alvarez, I.B., Neuenschwander, P.F., Sherman, D.R., et al. Early secreted antigenic target of 6-kDa protein of Mycobacterium tuberculosis primes dendritic cells to stimulate Th17 and inhibit Th1 immune responses. J Immunol 189 (2012), 3092–3103.
17. 17 Kassa, D., Ran, L., Geberemeskel, W., Tebeje, M., Alemu, A., Selase, A., et al. Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis. Clin Vaccine Immunol 19 (2012), 1907–1915.
18. 18 Chen, L., Xu, M., Wang, Z.Y., Chen, B.W., Du, W.X., Su, C., et al. The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85B, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunol Med Microbiol 59 (2010), 42–52.
19. 19 Grover, A., Ahmed, M.F., Singh, B., Verma, I., Sharma, P., Khuller, G.K., A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 8 (2006), 2390–2399.
20. 20 Young, S., O'Donnell, M., Lockhart, E., Buddle, B., Slobbe, L., Luo, Y., et al. Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin. Immunol Cell Biol 80 (2002), 209–215.
21. 21 Moreira, A.L., Tsenova, L., Murray, P.J., Freeman, S., Bergtold, A., Chiriboga, L., et al. Aerosol infection of mice with recombinant BCG secreting murine IFN-gamma partially reconstitutes local protective immunity. Microb Pathog 29 (2000), 175–185.
22. 22 Wiker, H.G., Harboe, M., The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol Rev 56 (1992), 648–661.
23. 23 Horwitz, M.A., Harth, G., Dillon, B.J., Maslesa-Galic, S., Recombinant bacillus Calmette–Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 (2000), 13853–13858.
24. 24 Kanbe, T., Akimoto, S., Allelic and genotypic diversity in long-term asexual populations of the pea aphid, Acyrthosiphon pisum in comparison with sexual populations. Mol Ecol 18 (2009), 801–816.
25. 25 Brunner, P.C., Douglas, M.R., Osinov, A., Wilson, C.C., Bernatchez, L., Holarctic phylogeography of Arctic charr (Salvelinus alpinus L.) inferred from mitochondrial DNA sequences. Evolution 55 (2001), 573–586.
26. 26 Monzon-Arguello, C., Garcia de Leaniz, C., Gajardo, G., Consuegra, S., Less can be more: loss of MHC functional diversity can reflect adaptation to novel conditions during fish invasions. Ecol Evol 3 (2013), 3359–3368.
27. 27 Shorten, R.J., McGregor, A.C., Platt, S., Jenkins, C., Lipman, M.C., Gillespie, S.H., et al. When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak. J Antimicrob Chemother 68 (2013), 543–549.
28. 28 Singh, S., Saraav, I., Sharma, S., Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis. Vaccine 32 (2014), 712–716.
29. 29 Gupta, A., Kaul, A., Tsolaki, A.G., Kishore, U., Bhakta, S., Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 217 (2012), 363–374.
30. 30 Caceres, N., Llopis, I., Marzo, E., Prats, C., Vilaplana, C., de Viedma, D.G., et al. Low dose aerosol fitness at the innate phase of murine infection better predicts virulence amongst clinical strains of Mycobacterium tuberculosis. PLoS One, 7, 2012, e29010.
31. 31 Bhatter, P., Mistry, N., Fitness of acquired drug resistant Mycobacterium tuberculosis isolates from DOTS compliant patients. Tuberculosis (Edinb) 93 (2013), 418–424.